Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.31 |
| ▸ | CTSD | P07339 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1567593 | 0.81 | PIK3CD (0.33) | PIK3CD | |
| SCHEMBL2028296 | 0.73 | PSEN1 (0.36) | PIK3CDCNR1CNR2FFAR2CTSD | |
| SCHEMBL3643875 | 0.73 | PSEN1 (0.36) | PIK3CDCNR1CNR2FFAR2CTSD | |
| SCHEMBL2024919 | 0.73 | GAA (0.41) | FFAR2 | |
| SCHEMBL5065098 | 0.73 | PIK3CD (0.36) | PIK3CD | |
| SCHEMBL1861018 | 0.69 | GPR88 (0.39) | — | |
| SCHEMBL14321919 | 0.68 | CTSD (0.39) | PIK3CDCNR1CNR2CTSD | |
| SCHEMBL2028714 | 0.67 | PSEN1 (0.30) | — | |
| SCHEMBL2029634 | 0.67 | PSEN1 (0.30) | — | |
| SCHEMBL2023553 | 0.67 | PSEN1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160300-A1 | Renin Inhibitors and Methods of Use Thereof | VITAE PHARMACEUTICALS, INC. | 2011-06-30 | — | — | US | disclosed |
| US-20100160424-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160424-A1 | RENIN INHIBITORS | ACE, REN, DNPEP | PIK3CD 4404/4885CNR1 4564/4885CNR2 4689/4885 |
| US-20110160300-A1 | Renin Inhibitors and Methods of Use Thereof | REN, ACE, AGTR1 | PIK3CD 3081/4885CNR1 3125/4885CNR2 4139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.